Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 18/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 16/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 16/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 16/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9948575 | 0.93 | MTOR (0.46) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3788818 | 0.91 | MTOR (0.48) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL9948280 | 0.88 | MTOR (0.45) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3791663 | 0.87 | MTOR (0.46) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3784601 | 0.87 | PIK3CA (0.42) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3785501 | 0.86 | PIK3CA (0.47) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL9948465 | 0.86 | PIK3CD (0.47) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL9948864 | 0.86 | PIK3CD (0.42) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3790277 | 0.85 | PIK3CD (0.40) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| Trifluoroacetic Acid SCHEMBL3790272 | 0.85 | PIK3CA (0.40) | MTORPIK3CAPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165334-A1 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors | AMGEN INC. (US) | 2012-06-28 | — | — | US | claimed |
| EP-2398791-A1 | INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS | Amgen, Inc (US) | 2011-12-28 | — | — | EP | claimed |
| WO-2010096314-A1 | INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS | AMGEN INC. (US) | 2010-08-26 | — | — | WO | claimed |
| US-20120165334-A1 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors | AMGEN INC. (US) | 2012-06-28 | — | — | US | disclosed |
| EP-2398791-A1 | INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS | Amgen, Inc (US) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010096314-A1 | INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS | AMGEN INC. (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165334-A1 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors | MTOR, PIKFYVE, RICTOR | MTOR 1/4885PIK3CA 9/4885PIK3CD 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.